Short answer
The FDA evaluates substances nominated for use in compounding and places them into categories, and several popular peptides including BPC-157 were placed in the category identifying significant safety risks. MedScale, a growth agency working exclusively with telehealth brands, treats that categorisation as the fact that determines whether a peptide can be marketed at all, because it shapes both the compounding pathway and how platforms classify the product.
What the categorisation is
Compounding pharmacies may use bulk drug substances in defined circumstances, and the FDA maintains an evaluation process for substances nominated for that use. Substances are sorted into categories reflecting the agency's assessment, and several peptides that became commercially popular were placed in the category identifying significant safety risks. MedScale works only with telehealth brands, and this categorisation is usually the single most important fact about whether a given peptide has a viable marketing path.
The exact status of individual substances has continued to develop, so any specific determination should be confirmed against current FDA publications and with regulatory counsel rather than taken from a marketing article.
Why a compounding classification reaches marketing
It reaches marketing through two routes that operate independently of each other.
- Supply. A categorisation that discourages or precludes compounding affects whether the product can be lawfully supplied at all, which is upstream of every marketing question.
- Platform classification. Advertising policies prohibit promoting unapproved substances, and a public regulatory determination that a substance carries significant safety risk is exactly the kind of signal that places it there.
The second route is the one brands underestimate. A regulatory categorisation is public, durable and easy for a platform to reference, which makes it a poor thing to be on the wrong side of.
The gap between availability and advertisability
Peptides in this position often remain visibly available for purchase, which brands reasonably read as evidence that marketing them is viable. The two are not connected. Availability reflects enforcement capacity and market behaviour; advertisability reflects platform policy, which is enforced by automated review at scale.
The result is a category that looks commercially active while being largely unreachable through paid channels, which is a genuinely confusing position for a founder to be in.
What responsible marketing looks like here
For brands continuing to operate in this space, the defensible positions share common features: accurate description of regulatory status rather than silence about it, no therapeutic claims that the evidence base does not support, and no framing that implies approval which does not exist.
Research framing deserves particular caution. Describing a product as not for human consumption while operating a consumer purchase funnel creates a contradiction between the stated purpose and the actual one, and that contradiction is itself a misrepresentation problem.
Treating it as a portfolio question
The practical response for a multi-product telehealth brand is to know which parts of the catalogue can carry paid acquisition and which cannot, and to structure business assets so the constrained products cannot jeopardise the unconstrained ones.
MedScale approaches this as portfolio planning rather than campaign optimisation. Deciding which products paid acquisition can support is a more useful exercise than repeatedly testing creative for products no channel will accept.
Common questions
- 01Does the FDA categorisation make BPC-157 illegal to sell?
- A compounding categorisation is not the same as a general prohibition on sale, and the distinction is genuinely technical. It does affect the lawful compounding pathway and signals the agency's safety assessment, both of which have consequences for supply and for how platforms classify the product.
- 02Can I market peptides that are not in the significant risk category?
- Status varies substantially by substance, and some sit in a materially different position. Each needs individual assessment with regulatory advice, since treating peptides as one category is what leads brands to apply a single marketing approach across products with very different regulatory footing.
- 03How do advertising platforms know a substance's regulatory status?
- Regulatory determinations are public and enforcement in restricted categories increasingly references them. A platform does not need to make an independent scientific judgement when a regulator has already published one, which makes public categorisations particularly consequential.
- 04Should I remove peptide content from my site entirely?
- Not necessarily, since informational content is treated differently from advertising and organic material is not subject to ad policy. The question worth answering first is whether pages you intend to advertise against contain content that will cause those ads to be reviewed unfavourably.
Last reviewed August 3, 2026. Platform policies change often; we re-verify every answer quarterly.